SCHEMBL5187217

SCHEMBL5187217

Cc1cc(C)cc(Nc2ccc(O)c3c2C(=O)c2ccccc2C3=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.59
▸ MEN1 O00255 6/20 0.59
▸ KMT2A Q03164 6/20 0.59
▸ TDP1 Q9NUW8 4/20 0.59
▸ MAPK1 P28482 3/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ RAB9A P51151 2/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ LMNA P02545 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59
▸ MAOA P21397 2/20 0.54
▸ P2RY4 P51582 5/20 0.54
▸ P2RY12 Q9H244 3/20 0.54
▸ TP53 P04637 1/20 0.52
▸ PRKCA P17252 2/20 0.52
▸ P2RY2 P41231 4/20 0.46
▸ P2RY6 Q15077 2/20 0.46
▸ P2RY1 P47900 1/20 0.46
▸ POLB P06746 2/20 0.46
▸ HPGD P15428 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13921521 0.89 PRKCA (0.58) MAPTMEN1KMT2ATDP1MAPK1
SCHEMBL28085383 0.87 MEN1 (0.57) MAPTMEN1KMT2ATDP1MAPK1
SCHEMBL29353964 0.87 MAPT (0.67) MAPTMEN1KMT2ATDP1MAPK1
SCHEMBL39659 0.87 MAPT (0.67) MAPTMEN1KMT2ATDP1MAPK1
SCHEMBL10622852 0.87 MAPT (0.60) MAPTMEN1KMT2ATDP1MAPK1
SCHEMBL305741 0.85 MAPT (0.52) MAPTMEN1KMT2ATDP1MAPK1
Formaldehyde SCHEMBL27614219 0.84 MAPT (0.64) MAPTMEN1KMT2ATDP1MAPK1
SCHEMBL16985236 0.84 MAPT (0.56) MAPTMEN1KMT2ATDP1MAPK1
SCHEMBL29500408 0.83 MEN1 (0.70) MAPTMEN1KMT2ATDP1MAPK1
SCHEMBL341146 0.83 MEN1 (0.70) MAPTMEN1KMT2ATDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1288192-B1 Process for preparing 1-amino-4-hydroxyanthraquinones LANXESS DEUTSCHLAND GMBH (DE) 2007-07-18 — — EP disclosed
US-6884899-B2 Preparation of 1-amino-4-hydroxyanthraquinones BAYER AKTIENGESELLSCHAFT (DE) 2005-04-26 — — US disclosed
US-20030045735-A1 Preparation of 1-amino-4-hydroxyanthraquinones LANXESS DEUTSCHLAND GMBH (DE) 2003-03-06 — — US disclosed
EP-1288192-A1 Process for preparing 1-amino-4-hydroxyanthraquinones Bayer Aktiengesellschaft (DE) 2003-03-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045735-A1 Preparation of 1-amino-4-hydroxyanthraquinones PAH, CYP1A1, DHPS MAPT 2185/4885MEN1 1813/4885KMT2A 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback